Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Sintilimab + GM-CSF in Advanced NSCLC
NCT04106180Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and sargramostim in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Overall Objective Response Rate. Status: unknown.
02
Drugs
sintilimabsargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04106180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106180.